Download
Download by
Scanning QR Code
No matches yet
Please check network settings and try again Refresh
Loading
Futu Hot Stocks
    Latest News
    History record delete
      Quotes All >
      News All >
      Help All >

      • Download app

        Download app

      • Online Inquiry

        Log in to access Online Inquiry
      +
      Congratulations
      You've successfully got advanced quotes worth 5000 HKD
      Download APP >>
      Quotes
      Detailed Quotes
      Company Overview
      Company ProfileCompany Executives
      Financial Analysis
      Main CompositionKey IndicatorsFinancial Statement
      Multi-dimentional Analyses
      Company Valuation Capital Tracking Short Selling Data
      Futubull > Quotes > GLMD Galmed Pharmaceuticals > Detailed Quotes

      GLMD Galmed Pharmaceuticals

      Watchlist
      0.615
      -0.035-5.35%
      Close 07/01 16:00 ET
      0.61500.00%
      Post Mkt Price 07/01 16:00 ET
      Giving away premium quotes worth 5000 HKD/year to unlock more data
      Get NOW
      High
      0.699
      Open
      0.643
      Turnover
      25.82K
      Low
      0.585
      Pre Close
      0.650
      Volume
      40.76K
      Market Cap
      15.43M
      P/E(TTM)
      Loss
      52wk High
      3.420
      Shares
      25.09M
      P/E(Static)
      Loss
      52wk Low
      0.417
      Float Cap
      12.17M
      Bid/Ask %
      -66.67%
      Historical High
      27.060
      Shs Float
      19.79M
      Volume Ratio
      0.24
      Historical Low
      0.417
      Dividend TTM
      --
      Div Yield TTM
      100
      P/B
      0.63
      Dividend LFY
      --
      Div Yield LFY
      16254.88%
      Turnover Ratio
      0.21%
      Amplitude
      17.52%
      Avg Price
      0.633
      Lot Size
      1
      Float Cap
      12.17M
      Bid/Ask %
      -66.67%
      Historical High
      27.060
      Shs Float
      19.79M
      Volume Ratio
      0.24
      Historical Low
      0.417
      Dividend TTM
      --
      P/B
      0.63
      Dividend LFY
      --
      Turnover Ratio
      0.21%
      Amplitude
      17.52%
      Avg Price
      0.633
      Lot Size
      1
      Post-Market
      5D
      1D
      1W
      1M
      1Q
      1Y
      Price Forecast

      No Data

      News

      Comment

      News

      Announcement

      Report

      Company Overview More
      Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
      CEO： Baharaff, Allen
      Market： NASDAQ
      Futu Hot List
      USHKCN
      TradeSearchNews
      SymbolLatest price%Chg

      Loading...

      Watchlist
      Back to the Top